Year: 2012
Type: article
Abstract: Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC.
Source: Hereditary Genetics
Author: Kartik Aysola Akshata Desai
Institutions: Grady Health System, Morehouse School of Medicine
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Awards: Morehouse School of Medicine Center of Excellence Research Endowment Program, Morehouse School of Medicine G12 Multidisciplinary Biomedical Research Center, Research Centers in Minority Institutions Clinical Rese*, 1/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership
OpenAlex ID: W2111786429
